Prerana B. Jadhav

Dr. Prerana B. Jadhav


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
PJPrerana B. Jadhav
Prerana B. Jadhav
SJShailaja Bhanudas Jadhav
Shailaja Bhanudas Jadhav
MZMehrukh Zehravi
Mehrukh Zehravi
Mohammad MubarakMohammad Mubarak
Mohammad Mubarak
FIFahadul Islam
Fahadul Islam
MAMohd Fahami Nur Azlina
Mohd Fahami Nur Azlina
Dipeptidyl peptidase-4 (DPP-IV) inhibitors are known as safe and well-tolerated antidiabetic medicine. Therefore, the aim of the present work was to synthesize some carbohydrazide derivatives (1a–5d) as DPP-IV inhibitors. In addition, this work involves simulations using molecular docking, ADMET analysis, and Lipinski and Veber’s guidelines. Wet-lab synthesis was used to make derivatives that met all requirements, and then FTIR, NMR, and mass spectrometry were used to confirm the structures and perform biological assays. In this context, in vitro enzymatic and in vivo antidiabetic activity evaluations were carried out. None of the molecules had broken the majority of the drug-likeness rules. Furthermore, these molecules were put through additional screening using molecular docking. In molecular docking experiments (PDB ID: 2P8S), many molecules displayed more potent interactions than native ligands, exhibiting more hydrogen bonds, especially those with chloro- or fluoro substitutions. Our findings indicated that compounds 5b and 4c have IC50 values of 28.13 and 34.94 µM, respectively, under in vitro enzymatic assays. On the 21st day of administration to animals, compound 5b exhibited a significant reduction in serum blood glucose level (157.33 ± 5.75 mg/dL) compared with the diabetic control (Sitagliptin), which showed 280.00 ± 13.29 mg/dL. The antihyperglycemic activity showed that the synthesized compounds have good hypoglycemic potential in fasting blood glucose in the type 2 diabetes animal model (T2DM). Taken all together, our findings indicate that the synthesized compounds exhibit excellent hypoglycemic potential and could be used as leads in developing novel antidiabetic agents.

23 April 2025 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
PJPrerana B. Jadhav
Prerana B. Jadhav
SWShital Vilas Wagh
Shital Vilas Wagh
MDManjushri Pratap Dabhade
Manjushri Pratap Dabhade
Background The need for new antibacterial medicines arises from the emergence of antibiotic-resistant bacterial strains. Pyranopyrazole derivatives, known for their diverse biological activities, are investigated for their potential to inhibit glucosamine-6-phosphate synthase, a critical enzyme in bacterial cell wall biosynthesis.Materials and Methods Pyranopyrazole derivatives (SW1-SW10) were synthesized via a one-pot multicomponent reaction. In silico ADME and toxicity analyses were conducted to predict pharmacokinetic profiles and potential toxicities. Molecular docking studies were conducted to evaluate binding affinities with glucosamine-6-phosphate synthase (PDB ID: 2VF5). The in vitro antibacterial activity was assessed by measuring the zones of inhibition against Escherichia coli and Staphylococcus aureus at concentrations of 25 µg/mL, 50 µg/mL and 100 µg/mL.Results The docking investigations indicated that SW6 and SW4 exhibited robust binding affinities, with docking scores of -9.4 and -9.0, respectively. In silico ADME analysis indicated favorable drug-likeness, with SW1, SW2, SW7 and SW10 meeting all criteria and showing bioavailability scores of 0.55. In vitro antibacterial experiments revealed that SW6 displayed the greatest efficacy, with inhibition zones measuring 9.5±0.2 mM, 14.6±0.5 mM and 20.3±0.7 mM against E. coli and 10.2±0.3 mM, 15.2±0.6 mM and 21.3±0.8 mM against S. aureus at escalating doses. SW4 exhibited comparable efficacy, with inhibition zones measuring 20.8±0.3 mM and 20.2±0.7 mM at 100 µg/mL against S. aureus and E. coli, respectively.Conclusion The pyranopyrazole derivatives, particularly SW6 and SW4, exhibit strong potential as antibacterial agents. Their high binding affinities and significant in vitro antibacterial activity suggest that these compounds could be promising leads for developing new antibacterial therapies targeting antibiotic-resistant strains.